Pharmaceuticals company Sun Pharmaceutical Industries announced Q3FY26 results Sales at Rs 154,691 million, a growth of 15.1%. Global Innovative Medicines sales stood at USD 423 million, including USD 55 million milestone payment. Global Innovative Medicines sales up 13.2%, accounting for 21.2% of sales, both Ex-milestone. EBITDA was Rs 49,485 million, up 23.4%. EBITDA margin was 31.9%. Profit before exceptional items and tax was Rs 47,166 million, up 24.4%. Net profit was Rs 33,688 million, up 16.0%. R&D investment was Rs 8,928 million at 5.8% of sales. Kirti Ganorkar, Managing Director, said: “Our results this quarter demonstrate well?rounded growth across all businesses, prominently led by our Branded businesses in India, Emerging Markets and Global Innovative Medicines. Our innovative product offering has expanded further with the launch of Unloxcyt in the US and the introduction of Ilumya in India. Together, these new initiatives bring differentiated therapies and meaningful innovation closer to the patients.” All this is for information. This is not a buy/sell recommendation. Thank you, Technofunda24

#WatchOutFor#StockInNews

1,129 likes·12 comments